Erlotinib Hydrochloride

Product Description

Erlotinib hydrochloride is a reversible, potent EGFR tyrosine kinase inhibitor (IC₅₀ = 2 nM); it reduces EGFR autophosphorylation in intact tumor cells (IC₅₀ = 20 nM). Erlotinib is selective for cell lines showing PC-9 and H3255 mutations (IC₅₀ values are 7 and 12 nM, respectively, sparing wild-type and T790 mutant EGFR. Erlotinib shows antiproliferative effects in cancer cell lines in vitro and promotes differentiation of urothelial organoids. Orally bioavailable.

Solubility

Preparing Stock Solutions for Erlotinib Hydrochloride

The following data is based on the product molecular weight 429.90

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
0.2 mM	11.63 mL	58.15 mL	116.31 mL
1 mM	2.33 mL	11.63 mL	23.26 mL
2 mM	1.16 mL	5.82 mL	11.63 mL
10 mM	0.23 mL	1.16 mL	2.33 mL

Calculators

Background References

References are publications that support the biological activity of the product.

• Moyer Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res. 1997 PMID: 9354447
• Santos Urothelial organoids originating from Cd49f^high mouse stem cells display Notch-dependent differentiation capacity. Nat.Commun. 2019 PMID: 31562298